RAPP.US Rapport Therapeutics, Inc. Common Stock

Healthcare Pharmaceuticals USA Stocks
23.76 USD
Close of Nov 18, 2026
22.06 52.93
Market cap
USD 1.41B
P/E
-
P/B
3.76x
ROE
-39.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RAPP.US undervalued?

Graham number

The Graham number of Rapport Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Rapport Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Rapport Therapeutics, Inc. Common Stock yet.

Rapport Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other C…

Full company profile